Key Takeaways
- Revenue down, margins up: Revenue fell 8.6% YoY on negative rate variance, but EBITDA margin improved 100 bps to 11.8% as input costs stabilized.
- Volume story intact: API volumes grew 8.4% YoY despite geopolitical headwinds, with domestic volumes surging 20% YoY, offsetting export weakness.
- Capacity-led transformation underway: Multiple new plants (dermatology, oncology, salicylic acid, methylamine, Saykha) are commissioning now through April, targeting ₹1,000-1,200 cr incremental revenue at current prices.
- Export destocking nearing end: Management believes the destocking cycle is done and expects demand recovery in coming quarters, though Latin America may need one more quarter after Q2 2024.
- What to watch next quarter: Whether the negative rate variance actually stops as guided, the pace of export order recovery, and the initial sales contribution from the dermatology and salicylic acid plants.
Revenue & Volume Dynamics
- Negative rate variance drove the top-line miss: Revenue fell 8.6% YoY entirely because selling prices declined; blended volumes actually grew ~9% YoY, with API volumes up 8.4%.
- Domestic strength, export drag: Domestic revenue declined only ~4.5% while exports grew ~29% YoY, but the export mix shift hurt because export markets typically carry higher gross contribution and higher regulatory-approval margins. When the proportion of higher-priced export sales fell, selling prices took a double hit: from raw material price decline and from the lower export component.
- Pricing floor in sight: Current price levels are almost back to pre-COVID historical levels, and management does not see raw material and API prices going down further. Most major raw materials are already below pre-COVID levels and have stabilized.
- Negative rate variance should fade: The sharp YoY rate variance should stop or reduce significantly; a slight impact may still appear in March but will not be as sharp as the December quarter.
- Inventory overhang in Q4: The company carries 90-100 days of pipeline inventory, and some of that will be sold in the first half of the March quarter, which might impact performance. No inventory losses were taken in the December quarter because domestic sales were high and everything was sold; the impact came through in gross contribution itself.
Patil: "What we expect was that the margin should have grown, the gross margin should have grown even more. What happens in the API business, API and spec-chem business is that for every product, it is product specific, for every product there is certain markup in terms of absolute number per kg. So, what we have seen in the last quarter even if we compare it to the historical numbers of that markup, that markup has not been achieved."
Export Markets: Destocking & Recovery
- Export challenges concentrated in specific regions: Heightened interest rates, dollar shortages, destocking, and conservative ordering hurt certain export regions during FY24. Latin America suffered the most from all three factors.
- Destocking cycle ending: Management believes the export destocking cycle should now be done and hopes demand will pick up in coming quarters. The company is cautiously optimistic about an export turnaround on the back of anticipated interest rate reductions and the end of destocking.
- Latin America lagging: Demand recovery in Latin America is expected maybe one quarter after Q2 2024, as destocking there is almost getting over but not yet complete.
- Red Sea disruption manageable: Some raw material delays from European sources have occurred due to the Red Sea issue, and freight costs have risen. However, 50% of export shipments are FOB so the company is not affected; for the rest, revised rates have been obtained from customers.
Shah: "Yes, Latin America has suffered a lot due to major problems with dollar interest rates and dollar shortage and third was inventory de-stocking. So, we expect maybe another one quarter after the 2nd Quarter of this year, 2024, we expect demand to come up again, basically."
New Capacity Build-Out
- Multiple projects commissioning in a tight window: The Tarapur dermatology plant is in final stages with operational commencement anticipated by end of January 2024. The salicylic acid plant starts production in the first week of February, making the company the only manufacturer after China for this product in the Indian market. The methylamine project (dimethylamine, monomethylamine, trimethylamine) is expected to commission in March or April, with 50% consumption within the group and 50% sold outside. The Saykha greenfield specialty chemicals project, including a chlorosulfonation product line, will be operational by April end of the current calendar year.
- Oral oncology facility ready for audits: A new manufacturing plant dedicated to oral oncology/anti-cancer molecules has just begun; USFDA and EU audits are expected in calendar year 2024.
- Incremental revenue potential is material: New projects carry incremental revenue potential of ₹1,000 to ₹1,200 crores at current price levels. The standalone company plans to achieve around ₹4,000 to ₹4,500 crores from all projects.
- Utilization ramp and margin profile: New capacities are expected to reach 30-40% utilization in FY25, exiting at that level. At 30% utilization, new projects will be profitable. At optimal levels, EBITDA margins upwards of 18-20% are achievable; 15-16% should be easily achievable, and beyond 50% utilization, 15-16% should be attainable.
- Dermatology sales start in Q1: Some sales are expected to begin in Q1 after the plant becomes operational, with a target of 2,000 tons per month and a ramp-up within 6-7 months to ~30-40% utilization in the first year.
- Saykha captive consumption model: The majority (over 50%) of Saykha production will be self-consumed for one of the company's APIs, with side products sold outside; customers have already been spoken to.
Patil: "At the optimal level, when you go, as per the current market trend, those products are facing EBITDA margins upwards of 18% to 20%. But the thing is, once the capacity is launched, there might be some bit of price war. But still, we feel that 15% to 16% should be easily achievable from the newer products."
Formulation Business Evolution
- Strategic shift underway: The formulation business is growing due to a transition from contract manufacturing to own branded generic exports, with additional markets being opened, new product launches, and new market launches planned.
- Domestic CMO remains core: Pinnacle's core formulation business is domestic CMO, contributing about 40-50% of business; the plan is to maintain it at around 40%.
- Seasonality fading: The formulation business currently shows seasonality because it is new in many international markets with new product launches and market openings. Going forward, management does not foresee much seasonality impact.
- High growth expected: Management expects high growth over the next few years for the formulation segment, driven by approvals, product launches, and capacity enhancement. A number of new product launches and new market launches are planned over the next 24 months.
Margins & Cost Structure
- Gross margin improvement has further room: Gross margin improved on the back of stabilized input costs and operational efficiency, but management believes it should have grown more. The absolute per-kg markup for each product was not achieved in the December quarter due to the volatile falling trend continuing. If the company restores the basic markup over RMC cost, it can push the existing margin profile up by a couple of percent.
- Export mix matters for margins: The export market typically gives higher gross contribution and higher margins due to higher regulatory approval requirements. The lower proportion of export sales in the quarter created a double impact on selling prices.
- Operating leverage from new plants: Once the dermatology plant is commissioned and capacity ramps up, it will lead to operating leverage from the next fiscal year.
- Specialty chemicals growth ambition: The specialty chemical business can easily double once all production capacities come up. For FY25, management targets handsome growth of around 30-40%, though this depends on rate variation; if no further negative rate variation occurs, very high double-digit growth should be achieved.
Balance Sheet & Capital Allocation
- Debt reduced sharply: Debt-to-equity has been reduced to 0.47 from 1.4-1.5x, achieved despite significant CAPEX and a buyback earlier in the year.
- Not targeting debt-free status: Management is comfortable running debt-to-equity of 0.5 to 0.7 and is not looking for a debt-free company. Debt will be kept to a minimum level to avoid any cash crunch.
- CAPEX on track: Total CAPEX for FY24 is expected to remain between ₹250 cr to ₹300 cr.
- Interim dividend declared: The board recommended an interim dividend of ₹1 per share on 24th January 2024.
- USFDA inspection pending: The file has been passed to the ORA (inspection) department; all responses were reviewed and found adequate. The company may do a follow-up in January to request the pending inspection.
Patil: "We are very much comfortable to run a debt of around 0.5 to 0.7 in terms of debt-to-equity ratio. We are very much comfortable doing that. So, probably we are not looking for a debt-free Company, but yes, definitely we will keep debt to the minimum level so that it won't hamper, it won't create any cash crunch for the Company anytime in the near future."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Negative rate variance | Should stop or reduce significantly; slight impact possible in March but not as sharp as December quarter | March quarter |
| Dermatology plant operational | Final stages; operational commencement anticipated | End of January 2024 |
| Salicylic acid plant production start | First week of February | February 2024 |
| Methylamine project commissioning | March or April | March-April 2024 |
| Saykha greenfield project operational | By April end | April 2024 |
| Dermatology sales start | Some sales expected in Q1 after operational | Q1 FY25 |
| Dermatology capacity ramp-up | Target 2,000 tons/month; ~30-40% utilization in first year; ramp within 6-7 months | FY25 |
| New capacity utilization exit rate | 30-40% utilization for new capacities | FY25 exit |
| New capacity EBITDA margins | 15-16% easily achievable; 18-20% at optimal levels | At 50%+ utilization |
| Specialty chemicals growth | 30-40% growth target, contingent on no further negative rate variation | FY25 |
| Volume growth target | 10-15% volume growth including new capacity | Coming year and further years |
| Standalone revenue target | ₹4,000 to ₹4,500 crores from all projects | No date |
| Incremental revenue from new projects | ₹1,000 to ₹1,200 crores at current price levels | No date |
| Existing capacity volume growth | 5-10% volume growth target | No date |
| Gross margin improvement | Couple of percent improvement if basic markup over RMC cost is restored | No date |
| Latin America demand recovery | One quarter after Q2 2024 | Q3 2024 |
| USFDA oral oncology audit | EU and USFDA audits expected | Calendar year 2024 |
| FY24 CAPEX | ₹250 cr to ₹300 cr | FY24 |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Consolidated revenue | ₹608 cr, decline of 8.6% YoY |
| Consolidated EBITDA | ₹72 cr, margin at 11.8%, improved 100 bps YoY |
| Consolidated PAT | ₹37 cr, margin at 6.1%, improved 60 bps YoY |
| 9M FY24 revenue | ₹1,912 cr, decline of 3.2% YoY |
| 9M FY24 EBITDA | ₹234 cr, margin at 12.2%, improved 140 bps YoY |
| 9M FY24 PAT | ₹124 cr, margin at 6.5%, improved 90 bps YoY |
| Standalone revenue | ₹540 cr, decline of 13.8% YoY; contributed ~87% of consolidated revenue |
| Standalone domestic revenue | Declined ~4.5% YoY; domestic market contributed 67% of standalone revenue |
| Standalone export revenue | Grew ~29% YoY; export market contributed 33% of standalone revenue |
| API volume growth | ~8.4% YoY |
| Formulation segment revenue | ₹79.3 cr, growth of 58.7% YoY; exports contributed ~58% |
| Formulation segment 9M FY24 revenue | ₹257 cr, growth of 18.2% YoY |
| Gross margin | Improved ~15-20 bps QoQ |
| Selling prices vs September 2023 | ~7% lower on aggregate basis |
| CAPEX incurred 9M FY24 | ~₹162 cr; targeted total CAPEX for FY24: ₹250 cr to ₹300 cr |
| Debt-to-equity ratio | 0.47 on consolidated basis; historically 1.4 to 1.5x |
| Debtor days | 90 days for December 2023, down from ~100 days in March 2023 |
| Interim dividend | ₹1 per share recommended by Board |
| Volume growth target for coming year | 10% to 15% |
| Specialty chemical growth target for FY25 | Around 30% to 40% |
| Incremental revenue potential from new projects | ₹1,000 to ₹1,200 cr at current price levels |
| New capacity utilization expectation for FY25 | 30% to 40% |
| EBITDA margin expectation from new products | 15% to 16% initially, upwards of 18% to 20% at optimal utilization |
| Domestic pricing decline | ~24% YoY |
| Domestic volume growth | A little more than 20% YoY |
| Export volume decline | ~14.5% YoY |
| Export rate variation | Around minus 15 |